1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Cancer Drug News 22 DECEMBER 2014

Cancer Drug News 22 DECEMBER 2014

  • December 2014
  • -
  • Espicom Business Intelligence
  • -
  • 20 pages

Industry Trend Analysis - Disappointing First-Line Kadcyla Results Impacts HER2 Franchise
Industry Trend Analysis - Diagnostics Gaining Wider Utility In The Pharmaceutical Market
Industry Brief - Cyclacel Reports Enrolment For Sapacitabine Phase III AML Trial
Industry Brief - Janssen Launches Imbruvica In UK For r/r MCL And CLL
Industry Brief - TetraLogic Initiates Phase II Trial Of SHAPE In CTCL
Industry Trend Analysis - Another Partnership Advances Into BTK Inhibitor Field For Haematological Cancers
Industry Brief - CHMP Adopts Positive Opinion On Velcade For MCL
Industry Brief - FDA Approves Cyramza For Second-Line mNSCLC
Industry Trend Analysis - Gardasil 9 FDA Approval To Advance HPV Vaccine Landscape
Industry Brief - Lynparza Gains EU Approval For BRCA-Mutated OC
Industry Trend Analysis - Somatuline Depot To Procure Strong Sales Following FDA Approval For GEP-NET Indication
Industry Brief - Licence Extension For Malp-2 Offers New Possibilities To Fight Against PC
Industry Brief - Taiho Completes TAS-102 NDA Submission To FDA For MCRC
Industry Brief - Abraxane Approved In Japan For Unresectable PC
Industry Brief - Halozyme's PEGPH20 Gains EU Orphan Medicinal Product Designation For PC
Industry Brief - Novogen's TRXE-009 Becomes Highly Active In Preclinical Melanoma Studies
Industry Brief - First Phase II Trial Initiated For IPH2201 In H&N Cancer
Industry Brief - Genmab Reaches Milestone In DuoBody Platform Collaboration With Janssen
Industry Brief - Novartis Stops Development Work On AUY922
Industry Brief - Polaris' ADI-PEG 20 Gains Orphan Drug Designation
Industry Brief - Crescendo Receives Further Investment to Develop Humabody Therapeutics In Oncology
Industry Brief - Merck Gains BET Inhibitor Through OncoEthix Acquisition

Table Of Contents

Cancer Drug News 22 DECEMBER 2014

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests,  Opport

2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests, Opport

  • $ 47500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-company survey from VPGMarketResearch.com contains 1,650 pages and 890 tables. The report provides a granular strategic analysis of over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein ...

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.